The growing number of postmenopausal women worldwide translates into new challenges for clinicians as they strive to help women stay healthy during the second half of their lives and has drawn attention to the potentially lucrative hormone replacement therapy (HRT) market. Hormone Replacement Therapy, a new study from Decision Resources, Inc., identifies opportunities for novel products competing in this dynamic market.
Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) Positive Marketing Efforts Will Play a Key Role
Across the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), attitudes toward HRT vary widely. The clear challenge for companies developing HRT products lies in convincing women of the benefits of HRT for both symptom relief and disease prevention. We believe HRT is an area that will continue to provide lucrative opportunities for companies able to effectively market new agents that offer convenience, safety, and protection against some of the long- and short-term effects of menopause.
Wyeth-Ayerst Will Maintain An Edge in the HRT Market
The huge size of the U.S. market relative to the European and Japanese markets for HRT, coupled with U.S. women's preference for oral products, means that the top sellers among combination oral products are, and will remain, Wyeth-Ayerst's Prempro and Premphase products, which combine conjugated equine estrogen (CEE) with medroxyprogesterone acetate (MPA). In Europe, where MPA and CEE are not as highly regarded as other forms of estrogen and progestogen, several other oral combinations are used. The most promising oral combinations under development include Aventis/Wyeth-Ayerst's estradiol-trimegestone and CEE-trimegestone combinations. Trimegestone promises to have a more benign side-effect profile than other progestogens currently on the market, and its launch as part of these combinations is enthusiastically awaited. These drugs' entry will help boost sales of oral combination products from $850 million in 2000 to almost $1.5 billion in 2010.
Selective Estrogen Receptor Modulators (SERMs) Are Poised to Capture Market Share
In recent years, raloxifene (Eli Lilly's Evista) has generated a swell of enthusiasm. However, it has become clear that this drug will not be able to replace HRT. Nevertheless, the market for SERMs has considerable growth potential in light of a growing trend toward switching older women to a SERM when symptoms of menopause abate. Two novel SERMs are in late-stage development: Wyeth-Ayerst/Ligand's TSE-424 and Pfizer/Ligand's lasofoxifene. Promising evidence has emerged from preliminary trials with these agents, as measured in terms of bone density markers, cholesterol levels, and lack of vasomotor side effects.
Hormone Replacement Therapy is a part of Mosaic, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or email@example.com.
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org.
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, +1-781-296-2553,